UCB has acquired Engage Therapeutics, Inc., a clinical-stage pharmaceutical company developing Staccato Alprazolam for the rapid termination of an active epileptic seizure, for $125 million in cash, and as much as $145 million in further potential milestone payments related to clinical development, submission and launch of Staccato Alprazolam. Charl van Zyl, Executive Vice President UCB and Head of Neurology said, “Like UCB, Engage is a company with a deep-seated passion in epilepsy. S...